Business opportunity
Scientists at the University of Oslo (Norway) have developed an innovative, scalable directional pump-less perfusion (dPP) organ-on-a-chip (OoC) platform that can transport cell culture media, circulating cells, bacteria and nanoparticles in a closed microfluidic circuit to interconnect different organ models.
Inven2 AS seeks investor/partners for establishing of a start-up or out-licensing of the IP.
Technology description
The group has developed a scalable, pump-less OoC device that generates a unidirectional, gravity-driven flow. Flow rate and oxygen levels for a venous and an arterial channel can be tuned “on-chip”. This platform allows vascularization of 3D organ models and possibly self-organisation in the future. The scientific group has established lab-scale fabrication, has shown proof-of-concept for several biological applications and advantages of the platform compared to state of the art.
Advantages
- User friendly
- Directional adjustable flow
- Air bubble proof
- Reproducibility
- No pumps or tubes needed
- Compatible with automatized liquid handling and imaging instruments
- Adjustable volume geometry
- High scalability
- Microscopy grade optical quality
- Multiple possible layouts with few technical constrains.
- Immune-enabled
- PDMS-free (no drugs absorption)
The dPP platform together with the scientist’s profound knowledge in induced pluripotent stem cell (iPSC) technology can be a game changer in the OoC field as it allows different studies from disease modelling to patient-specific drug testing.
PUBLICATIONS
The publication describing the platform https://doi.org/10.1039/D2LC00919F
IPR
The patent application for chip layout and functionality is filed in national phase.
